GlaxoSmithKline's Arranon Clears FDA For Refractory Leukemia & Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves nelarabine for treatment of twice-refractory T-cell leukemia and lymphoma patients Oct. 28.